AFINITOR
|
|
Generic name.
EVEROLIMUS
|
| Family.
MTOR inhibitors (Mammalian Target of
Rapamycin inhibitor)
|
| Source.
Derivative of Serolimus, which is a
produced by the actinobacteria Streptomyces Hygroscopicus.
|
| Mechanism of
action.
Everolimus is MTOR inhibitor. Inhibition
of MTOR results in decreased cell
proliferation and tumor angiogenesis.
|
| Cancer
treatment.
Metastatic renal cell carcinoma (clear
cell type) which progressed on previous
treatment with sunitinib or sorafinib
|
| Side effects.
Stomatitis, pneumonitis, rash, fatigue
|
|
Administration.
Oral tablets.
|
|
Another information.
Everolimus (also called Certican) is used
in the treatment of heart and kidney
transplant patients to reduce transplanted
organ rejection. Also, everolimus is used in
some drug-eluting stents to prevent coronary
arteries re-stenosis.
|
| References.
1) Motzer RJ et al. Efficacy of everolimus in advanced renal cell carcinoma:
a double blind, randomised, placebo-controlled phase III trial. Lancet 372:
449-456 (2008).
To read this article press here.
2) Eisen HJ. et al. Everolimus for the
prevention of allograft and vasculopathy in
cardiac transplant recipients. N Engl. J.
Med. 349: 847-858 (2003).
To read this article press here.
3) www.afiniotr.com
|
